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Abstract
Canine plasminogen is made up of seven domains. In each domain there are several cysteines that are linked by disulfide
bonds. Reduction of a limited number of the cystines destabilizes the protein such that it precipitates. The bond or bonds
that are broken provide about 14 kcal of stabilization energy. Circular dichroism and dynamic light scattering indicate that
there is probably an intermediate that is formed prior to precipitation and that the intermediate is somewhat larger than
the compact form of plasminogen.
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Introduction
Plasminogen (accession number P00747) is a blood protein with
multiple roles. It binds to many different chemical species; once
bound, it can be activated via proteolysis to plasmin [1,2]. The
major role for plasminogen is clearing the circulatory system of
blood clots [3–5]. Plasminogen is thought to play a key role in the
tissue remodeling that occurs during pregnancy [6,7] and that
which occurs during the metastasis of tumors [8,9]. Lastly,
plasminogen is thought to help in the propagation of bacterial
infections [10–12] as well as diseases associated with prions [13–
15].
Human plasminogen is a 791 amino acid containing protein
[16,17]. Activation occurs by cleaving a single peptide bond,
between residues 561 and 562 [18–20]. Activation can be rapid or
slow, the rate depending on the activator and the conformation
being acted upon. The activation process and its dependencies
have been reviewed [3,21,22].
There is no complete three dimensional X-ray structure for
plasminogen but the X-ray structures of six of the seven
individual domains are known. The sequence of domains is: the
N-terminal peptide followed by a series of five kringles followed
by a proteolytic domain at the carboxy-terminus. All plasmino-
gens have approximately the same structure. Canine plasminogen
(DPGN), the protein used in this work, consists of 793 residues
which include 24 disulfide bridged cystines (48 cysteines) [23].
There are multiple conformations of plasminogen and the protein
populates the various forms. There are three classical forms
which are dependent on ligand binding: two which are open
[24,25] and one which is closed; there are compact and relaxed
structures which are the result of high and low temperatures [26];
there are truncated open structures which are the result of
proteolysis of the N-terminal peptide. The conformation used in
this study was the full length, native, closed structure referred to
as Glu-plasminogen.
Many blood proteins are synthesized by the liver and
subsequently exported. Blood proteins frequently contain disulfide
bonds which result from the oxidation of cysteine residues that are
closely positioned in the three dimensional structure. Oxidation
does not usually take place in the cytosol of the cell in which
synthesis has occurred because the cytosol of most cells is buffered
at about 20.3 volts. In this reducing atmosphere, the majority of
cysteines will exist as free sulfhydryls. Blood proteins and other
exported proteins are oxidized as they leave the cytosol and enter
the endoplasmic reticulum [27]. In the case of plasminogen,
simultaneous export and oxidation must take place because the
intact protein is not soluble in the reduced state. This has been
shown to occur during synthesis of protein by HEPG2 cells
[28,29]; when synthesis occurs in the presence of dithiothreitol,
there is formation of aggregates which contain several different
protein species .This study shows that one or two of the 24
disulfide bridges in plasminogen are especially labile and, on
reduction, expose groups which bring about precipitation of the
protein.
Results and Discussion
Plasminogen was incubated with three reductants, mercapto-
ethanol, DTT (Cleland’s reagent), or tris(2-carboxyethyl)pho-
sphine (TCEP), and the change in light scattering monitored at
280 nm (Figure 1, top panel). Each of the four samples shown in
Figure 1 (top) has had the signals offset to higher values so that the
data can be easily seen. Figure 1 (top) shows that all three
reductants gave rise to a large change in A280. The change is the
result of precipitation of the protein. The time at which
precipitation occurred was dependent on the reductant and its
concentration. At higher concentrations, the precipitation oc-
curred more rapidly.
Figure 1 (top panel), also illustrates the time dependency. The
time at which the optical signal changed was 35 minutes when the
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The mixture of 0.133 M DTT and plasminogen, shown in the top
panel, was sampled and centrifuged at different times during the
incubation. Each precipitate was dissolved in SDS and run on
SDS-PAGE. The bottom panel of the figure shows the
composition of the centrifuged material. In the 0–8 minute time
frame there was no change in absorbance and no precipitate in the
centrifuged material. After that there was a rapid increase in A280
and in the amount of precipitate on the gel. The major band
migrated with authentic plasminogen. The experiment clearly
showed that in the presence of DTT changes in absorbance and
light scattering occurred at the same time as precipitation of the
plasminogen. When plasminogen was reduced by mercaptoetha-
nol or TCEP and the precipitate subjected to SDS-PAGE, similar
results were obtained. As absorbance changes, plasminogen
appears in the precipitate.
Dynamic light scattering can be used to monitor the period
between the onset of reduction and the formation of the
precipitate (Figure 2). Dynamic light scattering measures light
that is scattered from a tightly focused laser. The light scattered by
Figure 1. Reduction of 1.8 mM DPGN leads to precipitation. (Top panel) Plasminogen was treated with mercaptoethanol, dithiothreitol or
TCEP at the concentrations shown in the figure. Precipitation was followed by monitoring the change in light scattering/Absorbance at 280 nm. The
starting absorbance was about 0.4. Each curve has been offset for ease of viewing. The buffer was 5 mM K2HPO4, 5 mM KH2PO4, 100 mM NaCl, pH 7;
the temperature was maintained at 20uC. (Bottom panel) At the times indicated in the figure, 0.1 mL of the sample containing 0.133 M dithiothreitol
was removed from the cuvet and immediately centrifuged at 13 000 rpm. The precipitate and supernate were separated. SDS sample buffer was
added to each. Both were subjected to SDS-PAGE on 7% gels. The precipitates are shown in the figure. The gels of the supernates were not
sufficiently stained with Coomassie Brilliant Blue as to make the plasminogen easily visible.
doi:10.1371/journal.pone.0006196.g001
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and is dependent only on the diffusion coefficients of the particles
and the viscosity of the medium containing the particles. In the
main panel of Figure 2, extremely large particles started to appear
at about minute 75 when plasminogen was reduced with 41 mM
TCEP. The inset to the figure indicates that there was an
intermediate particle that started to appear immediately in the
presence of the reductant. The intermediate was maintained until
there was major aggregation. In addition, whereas the Stokes’
radius of native plasminogen in the absence of an opening ligand
was close to 4 nm, the size of the intermediate was significantly
larger than that of the native, closed, protein. The rate and
persistence of the intermediate was dependent on the concentra-
tion of DPGN and reductant as well as the identity of the
reductant.
The presence an intermediate(s) whose size is somewhat larger
than that of the native species may be indicative of a molten
globule [30] type state or states between the native and the
precipitate. The molten globule is postulated to have an expanded
core relative to the native protein resulting in a somewhat larger
molecule with a greater Stokes’ radius (see Figure 2, inset). In
addition, the molten globule is postulated to expose hydrophobic
surfaces that had been sequestered in the native protein. ANS [31–
33] has been used as a probe of newly exposed hydrophobic
surfaces and molten globules; it intercalates between exposed
hydrophobic surfaces. The view is that these newly exposed,
hydrophobic surfaces are sequestered from solvent in the majority
of native proteins but some become exposed when the protein is
induced to form a molten globule. The dynamic light scattering
data of Figure 3 show that ANS and reductant acted synergistically
to induce precipitation. The solid squares are the data in the
presence of ANS while the solid circles are the data in its absence.
The half time for the precipitation in the presence of ANS was
about half that in its absence. ANS, by binding to the newly
exposed hydrophobic sites, displaced the equilibrium between the
native form of plasminogen and the expanded intermediate; the
faster the expanded intermediate increased in concentration, the
faster precipitation occurred. Is it critical whether the intermediate
which forms on addition of reductant is a molten globule or some
other expanded form? What is important is that there is an
intermediate. That it may have characteristics of a molten globule-
like structure is suggested by the data on size, ANS enhancement
and finally by circular dichroism.
Circular dichroism can monitor protein secondary structure as
well as the disposition of aromatic groups and cystine. The
signature region for secondary structure is the far UV portion of
the dichroic spectrum (240 nm–180 nm). In the region of the
spectrum from 300 nm to 240 nm, the dichroic spectrum reports
on aromatics that are in an asymmetric environment and on the
cystines. When the far UV spectrum remains constant after a
change in conditions but the near UV changes, it frequently
indicates that one form of the probed molecule is molten globule
like compared to the other [30]. Figure 4 shows that the far UV
CD spectrum of plasminogen (top panel) was not influenced by
reduction; the spectra were essentially the same as previously
reported [34]. There are four curves in the top panel of Figure 4
and they superimpose. This indicates that the sum of the
secondary structure of the molecule stays more or less constant.
Native, full length plasminogen has an unusual far-UV CD
spectrum as can be seen from the figure. It is quite different from
the spectra of those proteins which consist primarily of alpha helix
and beta sheet. The spectrum of the protein is dominated the five
kringles which are very tight units, each tied together by three
disulfides. They contain neither beta sheet nor alpha helix but
have a well defined secondary structure that gives the character-
istic sharp minimum shown at about 203 nm.
By contrast, the bottom panel shows that reduction does
influence the near UV CD spectrum. This region results from the
Figure 2. Dynamic light scattering of DPGN after addition of reductant. DPGN was mixed with TCEP, filtered through a 0.02 mm Whatman
filter into a 20uC cuvet and the dynamic light scattering measurements started immediately. 2.4 mM DPGN, 41 mM (pH adjusted) TCEP, 170 mM KPi,
100 mM NaCl and 1 mM NaN3. The inset is an expanded version of the first 60 minutes of the reaction. K2HPO4 was used to adjust the pH of the TCEP.
doi:10.1371/journal.pone.0006196.g002
Reduction of Plasminogen
PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6196spectra of the three aromatic amino acids with a smaller
contribution from disulfide bonds. The aromatics are not optically
active themselves in the near UV but, when held rigidly in an
asymmetric environment, exhibit optical activity [35]. The
disulfide bond is inherently asymmetrical and exhibits optical
activity. Figure 4, the bottom panel, shows a slight loss of the CD
signal in the near UV. The difference spectrum shown in the inset
(0 TCEP–86TCEP) demonstrates that there is a major change in
the tryptophan spectrum. Since at least one disulfide is also
reduced, there must also be a change in the disulfide spectrum.
Loss of a portion of the tryptophan signal is probably the result of
loss of a selected asymmetric environment occurring near the
disulfide(s) that are reduced.
One of the compounds that binds to plasminogen is 6-
aminohexanoate (6-AH) (reviewed in [36]). When it binds it
causes the plasminogen to open and change its hydrodynamic
properties [24,37]. The 6-AH can bind to four (1,2,4,5) of the five
kringles, each of which has a different binding coefficient [38]; it is
only on binding to kringle 5 that the protein opens [39]. While
ANS enhances the rate at which the plasminogen precipitates, 6-
AH inhibits the precipitation reaction as shown in Figure 5. The
inhibition is specific. Glycine, which is a zwitterionic homologue of
6-AH and which similarly influences the dielectric coefficient of
the medium, does not inhibit the precipitation reaction. Can this
information be used as a guide to indicate which disulfide
reductions are responsible for aggregation?
The structures of the kringles and the catalytic domain of
plasminogen are well established [40–43]. There are a total of 24
disulfides in the intact plasminogen of which 16 are in the kringles,
with three per kringle and one between kringles 2 and 3. Kringles
1, 2, 4, and 5 bind 6-AH and contain tryptophan residues which
are quite near (3.2 s) the disulfides. Disruption of any of the 12
disulfides which are in the 6-AH-binding kringle domains could
lead to changes in the CD signal due to tryptophan. Other
possibilities cannot be ruled out: (1) The bridge between kringles
two and three is the disulfide bridge the reduction of which leads
to precipitation. (2) 6-AH acts indirectly by causing the DPGN to
open and it is only the closed protein which will precipitate. The
disulfides in the kringles are most likely those that are responsible
for the behavior of plasminogen following reduction.
How many disulfides are involved in the steps leading to
precipitation? Mercaptoethanol and dithiothreitol (DTT) are
poorly suited to answering this question. TCEP is a strong
reductant with significant specificity for disulfides [44]. It was used
in this study to count disulfides since it is not easily oxidized by
molecular oxygen [44]. At high concentrations of DPGN and
TCEP (.25 mM), precipitation was rapid and complete at ratios
of 3 TCEP:1 DPGN (data not shown). This probably indicates
that fewer than three disulfides need to be reduced prior to
forming the species that precipitates. Mass spectrometry was used,
unsuccessfully, to try to deduce which disulfides were reduced
under these conditions.
DPGN is extremely stable at room temperature in most buffers
as long as there is no major activation of the protein to plasmin.
Oxygen has no deleterious effects that can be easily measured.
This stability ensures that in the oxidizing atmosphere of the
blood, the molecule is not rapidly degraded. The fact that
reductants can bring about a destabilization of the protein affords
an opportunity to ask just how much stabilization energy is
provided by the disulfide bridges. The question can be answered
by setting the midpoint potential of the system, DPGN/reductant,
such that the system goes to equilibrium rather than completion.
The redox couple dithiothreitol/trans-dihydroxydithiane has a
midpoint reduction potential, E’u,o f20.33 V [45]. This value is
approximately the same as the reduction potential found inside the cell.I na n
anaerobic atmosphere there is no tendency for the DTT to
undergo air oxidation. The mixtures of DPGN, DTT and
dihydroxydithiane were prepared in a glove box in which the
Figure 3. The influence of ANS on the dynamic light scattering of 1 mM DPGN in the presence of 10 mM (pH adjusted) TCEP. The
solid squares are in the presence of 20 mM ANS whereas the solid circles are in its absence.
doi:10.1371/journal.pone.0006196.g003
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comparable concentration in air is 20% or 200 000 ppm. The
samples were incubated for 72 hours at 25uC in open Eppendorf
centrifuge tubes in the glove box. At the end of the incubation
period, the samples were capped while still in the glove box, then
removed and immediately centrifuged at 13 000 rpm for 10
minutes. The precipitates and supernates were separated. The
protein in the precipitates was monitored by SDS-PAGE. The
results are shown in Figure 6. The importance of the data in this
figure is the following: At ratios of DTT/Dihydroxydithiane that
are above 1:10, the protein precipitates. At ratios below 1:10, the
protein does not precipitate. At 1:10 DTT/Dihydroxydithiane
about 50% of the protein has precipitated. At this ratio, the
concentration of DTT is still 5 mM, well in excess of the
plasminogen. The driving force for the reaction is given by the
Nernst equation, expressed as an oxidation potential; it evaluates
to 0.3 volts or about 14 kcal.
E’~E’
0{RT=nF ln ox ½  = re ½  ðÞ
DG~{nFE’
The conclusion drawn from this calculation is: the disulfides of
plasminogen are functional. They stabilize the protein; the most
labile of the 24 disulfides provide about 14 kcal of stabilization
energy.
There are two aspects of the work that is reported here that are
of general interest:
1. Mammals are regularly subjected to infection by bacteria, are
constantly undergoing tissue remodeling, and are under constant
threat from both internal and external sources. That they do not
die every time a blood clot becomes lodged in a small artery is at
least in part because plasminogen recognizes the insult. Infection
with a pathogenic form of streptococci or a ‘‘scrapie’’ form of a
prion requires tight regulation of plasminogen activation in order
to control the infection. Cell debris from clots, as well as
plasminogen-bacterial complexes and prion-plasminogen com-
plexes can gain access to cell interiors. In the blood and in the
intercellular space, the complexes are in rapid solution-equilibri-
um. Once brought into the cell, regardless of the mechanism by
which entry occurs, the complexes are subjected to reducing
conditions. Plasminogen which is tightly bound to its ligands is
probably degraded at the same time as the ligand. Plasminogen
which has been internalized in the absence of ligand poses a threat
to the cell since it can now precipitate and thereby induce yet
another potential insult. It’s clear that this process must be
controlled and it will be interesting to determine just how it is
controlled.
2. Reductants induce precipitation without exerting a large
influence on the secondary or tertiary structure of plasminogen.
Precipitation is not a prerequisite for crystallization of proteins but
frequently provides a guide for determining the solubility of the
protein. We have carried out crystallization screens with canine
plasminogen and reductants. The screens have indicated some
formation of crystals. The best crystals have been grown in
solutions containing PEG 400, ammonium sulfate, HEPES and a
26excess of TCEP. So far the crystals have not been of a quality
that is appropriate for X-ray analysis. It is hoped that those who
work with the plasminogens from other species may have more
success.
In conclusion, the data presented in this report indicate that the
disulfides of plasminogen are necessary for maintaining the high
concentration, ca 2 mM, of plasminogen in plasma. As the
disulfides are reduced, hydrophobic surfaces must become
somewhat more exposed thereby reducing the solubility of the
protein, i.e., causing it to precipitate.
Materials and Methods
The blood used for the preparation of plasminogen was
obtained from the Montreal General Hospital, in 2005, following
Figure 4. The influence of TCEP on the circular dichroic
spectrum of DPGN. The top panel shows that the far UV spectra
down to 190 nm is not influenced by TCEP at ratios of TCEP to DPGN of
0, 2, 4 or 8. The protein concentration was 3.2 mM in the 0 TCEP sample
and 2 mM in the 16 mM TCEP sample. At these concentrations, the
plasminogen did not precipitate. The bottom panel shows that the near
UV spectrum of DPGN is disrupted by the TCEP; this region of the
spectrum is characteristic of the aromatic amino acid residues as well as
the disulfides. The concentration of plasminogen in the 0 TCEP solution
was 11.2 mM; in the 75 mM TCEP sample, the plasminogen concentra-
tion was 9.4 mM. At these concentrations, the protein did not
precipitate during the course of the measurements. In both panels,
the blanks were subtracted from the spectra and the resultant spectra
normalized for protein concentration. The inset of the bottom panel
shows the difference spectrum (0 TCEP - 8x TCEP) in the near UV. The
difference spectrum has been smoothed whereas the spectra in the two
main panels have not been smoothed. The difference spectrum is
dominated by a characteristic tryptophan spectrum but must also
contain a contribution from at least one disulfide.
doi:10.1371/journal.pone.0006196.g004
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the hospital ethics board. The blood was treated immediately with
sodium citrate such that the final concentration was about 15 mM.
The resulting plasma was ‘‘straw’’ colored and showed no
evidence of haemolysis. The preparation of plasminogen from
plasma has been extensively described [5]. After the final lysine
sepharose column, the protein was dialyzed against 10 mM
potassium phosphate, 100 mM NaCl, pH 7.0. 0.3 mM Aprotinin
(Fluka, St. Louis, MO) was added to the preparation at the time it
eluted from the lysine-sepharose column. The salts used in this
study were of ACS grade or better. 6-aminohexanoate (6-AH), 8-
anilinonaphthalene sulfonic acid (ANS), mercaptoethanol (MeSH),
Cleland’s reagent (dithiothreitol, DTT), trans-4,6-dihydroxy-1,2-
dithiane were from Fluka or Sigma (St. Louis, MO).
Figure 5. 6-aminohexanoic acid inhibits the precipitation reaction. DPGN (2.3 mM) was treated with 15 mM dithiothreitol in the presence or
absence of 26 mM 6-aminohexanoate. The buffer conditions were the same as in Figure 1.
doi:10.1371/journal.pone.0006196.g005
Figure 6. Precipitation of plasminogen by DTT/Dihydroxydithiane anaerobic mixtures. From left to right, the ratios are 1000:1, 100:1, 10:1,
1:1, 1:10, 1:100, 1:1000. At 1:10, about 50% of the plasminogen precipitates. E’ (as an oxidation potential) of the mixture at this ratio is about 0.3 V.
This gives a driving force of about 14 kcal for reduction of the plasminogen.
doi:10.1371/journal.pone.0006196.g006
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reductant was followed either with a Cary 2400 UV-VIS-NIR
spectrophotometer (Varian Instruments, Toronto, CA) at 280 nm
or with a Dyna-Pro dynamic light scattering apparatus (Wyatt
Instruments, Santa Barbara, CA). Both instruments were
thermostated, usually at 20uC. Samples were filtered through
Anotop 10, 0.02 mm inorganic membrane filters (Fisher Scientific
Co., Montreal, QC) prior to a measurement. Circular dichroic
spectra were obtained with a Jasco 815 polarimeter thermostated
at 20uC. The far UV spectra did not differ from those taken in
the past [34]. SDS-PAGE, on the precipitated plasminogen, was
carried out as previously described [46,47] using 7% gels. The
supernates were quite dilute (%0.2 mg/mL) and were not
monitored on gels.
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